个性化文献订阅>期刊> Journal of Infectious Diseases
 

Cumulative HIV Viremia during Highly Active Antiretroviral Therapy Is a Strong Predictor of AIDS-Related Lymphoma

  作者 Zoufaly, A; Stellbrink, HJ; an der Heiden, M; Kollan, C; Hoffmann, C; van Lunzen, J; Hamouda, O  
  选自 期刊  Journal of Infectious Diseases;  卷期  2009年200-1;  页码  79-87  
  关联知识点  
 

[摘要]Background. AIDS-related lymphoma contributes to significant morbidity and mortality among human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART). We assessed the predictive role of cumulative HIV viremia and other risk factors in the development of AIDS-related non-Hodgkin lymphoma.Methods. Data from the Clinical Surveillance of HIV Disease (ClinSurv) study, an ongoing, observational, open cohort study of HIV-infected patients from different urban areas in Germany, were analyzed using a Cox proportional hazards model.Results. In the Cox model, which comprised 6022 patients and 27,812 patient-years of follow-up while patients were receiving HAART from 1999 through 2006, cumulative HIV viremia was found to be independently associated with the risk of lymphoma (hazard ratio, [HR], 1.67 [95% confidence interval {CI}, 1.27-2.20]) (P<.001). This association differed markedly between lymphoma subtypes. Although the association was more pronounced for Burkitt-type lymphoma (HR, 3.45 [95% CI, 1.52-7.85]) (P = .003), there was no association between cumulative HIV viremia and the incidence of primary central nervous system lymphoma (HR, 1.00 [95% CI, 0.39-2.57]) (P = .997). Other risk factors associated with an increased risk in a multivariable analysis included the latest CD4 T cell count as well as age per 10-year increment.Conclusions. Cumulative HIV viremia is an independent and strong predictor of AIDS-related lymphoma among patients receiving HAART. The influence of cumulative HIV viremia may differ between lymphoma subtypes.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内